Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...

British pharmaceutical company GSK reported on Wednesday that its third-quarter profit before tax dropped to £64 million ($83 ...

GSK is the latest to turn its back on prominent ... a spokesperson told Fierce Pharma via email. “While individual members make their respective decisions annually on membership, BIO has never ...

Bearish flow noted in GSK (GSK) Pharma with 2,296 puts trading, or 1.2x expected. Most active are May-25 30 puts and Dec-24 38 calls, with total volume in those strikes near 2,500 contracts.

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the ...

GSK has spent slightly more on lobbying this year compared with 2023. The company spent $3.87 million in the first three ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

GSK has announced that it will be expanding its immunology pipeline by acquiring a clinical-stage T cell-engager from Chimagen Biosciences in a deal worth $850m. GSK said it plans to develop and ...